Do Options Traders Know Something About Retrophin (RTRX) Stock We Don't?Zacks Investment Research • 03/18/20
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisGlobeNewsWire • 03/09/20
Retrophin Recognizes Rare Disease Day 2020 and the Importance of Working Together Toward More Equitable Access to CareGlobeNewsWire • 02/28/20
Retrophin, Inc. (RTRX) CEO Eric Dube on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/25/20
Retrophin, Inc. (RTRX) CEO Eric Dube on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 10/31/19
Earnings Preview: Retrophin (RTRX) Q3 Earnings Expected to DeclineZacks Investment Research • 10/23/19
Biotech Stock Crashes To 3-Year Low After Its High-Risk Drug FailedInvestors Business Daily • 08/22/19
Retrophin's stock plunges after late-stage trial for PKAN treatment fails to meet targetsMarket Watch • 08/22/19
Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKANGlobeNewsWire • 08/22/19